€1.02
Your prediction
Rigel Pharmaceutical Inc. Stock
Pros and Cons of Rigel Pharmaceutical Inc. in the next few years
Pros
Cons
Performance of Rigel Pharmaceutical Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Rigel Pharmaceutical Inc. | -2.000% | -4.490% | -23.291% | -0.439% | -26.494% | -66.293% | - |
Ardelyx Inc. | 2.610% | -2.578% | -17.883% | 40.048% | 2.007% | -13.927% | - |
Salarius Pharmaceuticals Inc. | 1.400% | -2.727% | -46.500% | -69.209% | -22.883% | -98.244% | -99.994% |
Brainstorm Cell | -5.760% | 3.754% | -21.032% | -81.975% | 114.440% | -80.717% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Rigel Pharma (RIGL) is a biotechnology and medical research company that plays a crucial role in finding innovative solutions for the healthcare sector. An overview of the financial statements presents a mixed picture, with some positive trends as well as areas of concern.
*Pros: *
Revenues: Rigel Pharma's total revenues have been increasing year over year, with a significant uptick between 2020 and 2021, and a steady increase in 2022. This growth in revenue indicates that the company has been successful in generating profitable sales and expanding its business.
Comments